<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Pharmacy.html">
<title>Pharmacy RSS : Gourt</title>
<link>http://www.gourt.com/Health/Pharmacy.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2008-08-27T14:31+47:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Pharmacy RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119411.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119334.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119347.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119257.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119266.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119267.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119269.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119194.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119213.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119173.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119076.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119130.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119106.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119103.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119104.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118997.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118998.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118999.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119000.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119002.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118913.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118867.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118901.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118878.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118879.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119384.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119336.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119347.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119348.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119326.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119287.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/119180.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118921.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118868.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118899.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118897.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118765.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118709.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118628.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118625.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118484.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118406.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118408.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118294.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118279.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118113.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118114.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118116.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118049.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/118039.php" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01877.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01876.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01875.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01874.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01873.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01872.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01871.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01870.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01869.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01868.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01867.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01866.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01865.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01864.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01862.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/interioralaska08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/publix08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01875.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/peppersunlimited08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/wholefood08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/marspetcare08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/smenterprise08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/hoplee08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/homemade08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01873.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/cfsauer08_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/wegmans07_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01869.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/eglabs07_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/vitafood07_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/jackdistribution07_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/publix07_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/sausea07_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01864.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/agricola_zaragoza07_08.html" />
  <rdf:li rdf:resource="http://www.fda.gov/oc/po/firmrecalls/domega07_08.html" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://www.medicalnewstoday.com/articles/119411.php">
<title>New Cell Removal Technique Could Make Drugs Cheaper</title>
<link>http://www.medicalnewstoday.com/articles/119411.php</link>
<description><![CDATA[  A  new method to remove dead cells from the cell cultures that are  routinely used to manufacture protein-based drugs has been developed by  researchers at the University of Edinburgh.     Protein-based  drugs are ever more being prescribed to treat various diseases. To  produce these drugs, it is usually most efficient to harness the  efforts of cells in mass culture which have been given the ability to  produce the protein.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119334.php">
<title>Finalists Nominated For The 2008 European Biotechnica Award</title>
<link>http://www.medicalnewstoday.com/articles/119334.php</link>
<description><![CDATA[The three finalists of the 2008 EUROPEAN BIOTECHNICA AWARD have been determined. The biotechnology companies nominated are Cambridge-based Astex Therapeutics Limited (UK), GENEART AG from Regensburg (Germany) and immatics biotechnologies GmbH based in TÃ¼bingen (Germany). The prize, worth EUR 100,000, is awarded to innovative European biotechnology and life sciences companies.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119347.php">
<title>Manhattan Research Announces Top 10 Product Sites Visited By Physicians</title>
<link>http://www.medicalnewstoday.com/articles/119347.php</link>
<description><![CDATA[Diabetes treatment brand sites from Januvia, Actos, Byetta, and Avandia are among the top pharmaceutical product websites in terms of primary care physician visitation, according to a new from pharmaceutical and healthcare market research company Manhattan Research (www.manhattanresearch.com).      Breaking into this year's top product site list are Actos, Actonel, Amitiza, and Aciphex, proving to be successful in increasing physician awareness online.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119257.php">
<title>Anthera Pharmaceuticals Advances Global Development Strategy For Varespladib In Patients With Acute Coronary Syndrome</title>
<link>http://www.medicalnewstoday.com/articles/119257.php</link>
<description><![CDATA[Anthera Pharmaceuticals   Inc., a privately held biopharmaceutical company developing                     anti-inflammatory drugs,  announced the initiation of the FRANCIS   (Fewer Recurrent Acute coronary events with Near-term Cardiovascular        Inflammation Suppression) clinical trial designed to examine the impact of   varespladib when administered to patients within 96 hours of an Acute   Coronary Syndrome (ACS) event.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119266.php">
<title>New Trial To Evaluate Nexavar&#xAE; As Adjuvant Therapy In Liver Cancer</title>
<link>http://www.medicalnewstoday.com/articles/119266.php</link>
<description><![CDATA[Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the start of a Phase III study with Nexavar® (sorafenib) tablets in liver cancer. The randomized, double-blind, placebo-controlled study is evaluating Nexavar as an adjuvant therapy for patients with hepatocellular carcinoma (HCC), or primary liver cancer. An adjuvant treatment is given as an additional systemic therapy after the initial tumor treatment, e.g.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119267.php">
<title>Bayer HealthCare And Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement In Vision Over 52 Weeks In A Phase 2</title>
<link>http://www.medicalnewstoday.com/articles/119267.php</link>
<description><![CDATA[Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that patients with wet age-related macular degeneration (AMD) receiving VEGF Trap-Eye in a Phase 2 extension study on a PRN (as needed) dosing schedule continued to show highly significant improvements at 52 weeks in the primary and key secondary endpoints of retinal thickness (an anatomic measure of treatment effect) and vision gain.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119269.php">
<title>Patients Taking Cymbalta&#xAE; Experienced Reduced Chronic Low Back Pain In New Study</title>
<link>http://www.medicalnewstoday.com/articles/119269.php</link>
<description><![CDATA[Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score, compared with placebo.(1) Results from the double-blind, 13-week, placebo-controlled study of 236 patients were presented today at the annual congress of the European Federation of Neurological Societies (EFNS) in Madrid, Spain.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119194.php">
<title>Society Of Plastics Engineers&#x27; 2008 Research Award</title>
<link>http://www.medicalnewstoday.com/articles/119194.php</link>
<description><![CDATA[Dr. Dilhan M. Kalyon, Professor of Chemical Engineering and Director of the Highly Filled Materials Institute at Stevens Institute of Technology, has won the Society of Plastics Engineers' 2008 Research Award (in Memory of John C. Moricoli). Kalyon received his B.Eng. in Chemical Engineering in Ankara, Turkey, and his M. Eng. and Ph.D. in Chemical Engineering/Polymers at McGill University in Montreal, Canada.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119213.php">
<title>Research And Markets: The Top 10 World&#x27;s Leading Pharmaceutical Companies: Pfizer</title>
<link>http://www.medicalnewstoday.com/articles/119213.php</link>
<description><![CDATA[Research and Markets has announced the addition of the "The Top 10 World's Leading Pharmaceutical Companies: Pfizer" report to their offering.   In a highly dynamic and fragmented pharmaceutical market, besieged by intense competition, rapid pace of technological innovations and the uncertainty regarding future government regulations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important...]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119173.php">
<title>Chairman Announced For Eyeforpharma&#x27;s Patient Adherence And Persistence USA Summit 2008</title>
<link>http://www.medicalnewstoday.com/articles/119173.php</link>
<description><![CDATA[Tickets are now on sale for eyeforpharma's Patient Adherence, Persistence and Compliance USA Summit, October 23-24, Boston and are selling out fast. Last year the event sold out with over 200 delegates, a ratio of 80% pharma and over 90% positive feedback.    The chairman has been announced recently as Daryl J.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119076.php">
<title>Helping The Medicine Go Down</title>
<link>http://www.medicalnewstoday.com/articles/119076.php</link>
<description><![CDATA[Getting little Doug and Debbie to take a spoonful of medicine is more than just a rite of passage for frustrated parents. Children's refusal to swallow liquid medication - and their tendency to vomit it back up - is an important public health problem that means longer or more serious illness for thousands of kids each year. In the case of HIV and AIDS pediatrics, missing a dose can be a life or death scenario.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119130.php">
<title>FDA Approves ALOXI(R) (Palonosetron HCl) Capsules For Prevention Of Acute Chemotherapy Induced Nausea And Vomiting</title>
<link>http://www.medicalnewstoday.com/articles/119130.php</link>
<description><![CDATA[Eisai Corporation of   North America and its partner Helsinn Healthcare SA announced that   the U.S. Food and Drug Administration (FDA) has approved a new oral        formulation of ALOXI(R) (palonosetron hydrochloride) for the prevention of               chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules 0.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119106.php">
<title>Cymbalta Receives European Approval For The Treatment Of Generalised Anxiety Disorder</title>
<link>http://www.medicalnewstoday.com/articles/119106.php</link>
<description><![CDATA[Eli Lilly and Co (NYSE:   LLY) and Boehringer Ingelheim have announced that the European Commission   has approved the use of Cymbalta(R) (duloxetine) for the treatment of   Generalised Anxiety Disorder (GAD). This approval -- the fourth for           duloxetine in Europe -- was issued on 28 July following an initial positive   opinion issued by the European Medicines Agency's (EMEA) Committee for   Medicinal Products for Human Use (CHMP) on 26 June 2008.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119103.php">
<title>Indevus Pharmaceuticals Announces Completion Of Enrollment In Phase III Trial Of PRO 2000</title>
<link>http://www.medicalnewstoday.com/articles/119103.php</link>
<description><![CDATA[Indevus   Pharmaceuticals, Inc. (Nasdaq: IDEV) announced the completion of   enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the   Company's candidate vaginal microbicide for the prevention of HIV and other   sexually transmitted infections.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119104.php">
<title>Human Genome Sciences Completes Enrollment In Randomized Phase 2 Trial Of HGS-ETR1 In Non-Small Cell Lung Cancer</title>
<link>http://www.medicalnewstoday.com/articles/119104.php</link>
<description><![CDATA[Human Genome   Sciences, Inc. (Nasdaq: HGSI) announced that it has completed the   enrollment and initial dosing of patients in a randomized Phase 2 trial of   HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents   paclitaxel and carboplatin as first-line therapy in advanced non-small cell   lung cancer (NSCLC).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118997.php">
<title>Head-to-Head Study Showed Prasugrel Statistically Superior To Clopidogrel In Reducing Recurrent Cardiovascular Events</title>
<link>http://www.medicalnewstoday.com/articles/118997.php</link>
<description><![CDATA[A new,   pre-specified analysis of the landmark Phase III head-to-head TRITON-TIMI     38 study showed patients who took prasugrel for acute coronary syndromes   (ACS) managed with an artery-opening procedure known as percutaneous   coronary intervention (PCI) and had survived their first cardiov]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118998.php">
<title>FDA Requires Additional Information On DORIBAX For Treatment Of Hospital-Acquired Pneumonia</title>
<link>http://www.medicalnewstoday.com/articles/118998.php</link>
<description><![CDATA[Johnson & Johnson Pharmaceutical   Research & Development, L.L.C. (J&JPRD) announced that the U.S. Food   and Drug Administration (FDA) requires additional information before it   will approve the company's New Drug Application (NDA) for DORIBAX(TM)   (doripenem for injection) for the treatment of hospital-acquired pneumonia,   also known as nosocomial pneumonia (NP), including ventilator-associated   pneumonia (VAP).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118999.php">
<title>Bayer And Onyx Begin Enrollment In STORM Trial Studying Nexavar As Adjuvant Therapy For Patients With Liver Cancer</title>
<link>http://www.medicalnewstoday.com/articles/118999.php</link>
<description><![CDATA[Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.     (Nasdaq: ONXX) announced the companies have begun enrolling patients   in the STORM Sorafenib as Adjuvant Treatment in the Prevention of                Recurrence of Hepatocellular Carcinoma trial.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119000.php">
<title>Ardea Biosciences Advances Lead Product Candidate For The Treatment Of Gout, RDEA594, Into Phase 1 Clinical Trial</title>
<link>http://www.medicalnewstoday.com/articles/119000.php</link>
<description><![CDATA[Ardea Biosciences, Inc.         (Nasdaq: RDEA) announced that the Medicines and Healthcare products   Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1   study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the   Company's lead product candidate for the treatment of gout.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119002.php">
<title>Telik&#x27;s Proteasome Inhibitor Program Meets A Preclinical Development Milestone</title>
<link>http://www.medicalnewstoday.com/articles/119002.php</link>
<description><![CDATA[Telik, Inc.   (Nasdaq: TELK) announced that its novel small molecule proteasome   inhibitor program met a preclinical development milestone by demonstrating   anticancer activity in preclinical models of human leukemia. The proteasome   is an important cellular structure necessary for the growth and function of   cancer cells and inhibition of the proteasome has been shown to promote   cell cycle arrest and cancer cell death or apoptosis.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118913.php">
<title>The New MagNA Pure LC 2.0 System: New Design And Improved Performance Meet A Proven Nucleic Acid Isolation Technology</title>
<link>http://www.medicalnewstoday.com/articles/118913.php</link>
<description><![CDATA[A fast, flexible, and reliable isolation of pure nucleic acids from various sample materials is crucial for sensitive molecular analysis by PCR, RT-PCR, sequencing, arrays etc. In addition, automation of nucleic acid isolation is becoming increasingly important for reproducibility and to reduce experimental error. During the last years, demands regarding hardware design, software, and operating system have been increasing. The new MagNA Pure LC 2.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118867.php">
<title>States Consider Legislation To Restrict Access To Physician Prescribing Information For Data Mining Companies</title>
<link>http://www.medicalnewstoday.com/articles/118867.php</link>
<description><![CDATA[  A number of states have begun to consider legislation that would restrict access to physician prescribing information for data mining companies as part of a "backlash against pharmaceutical marketing efforts," the AP/Arizona Republic reports.  Data mining companies, such as ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118901.php">
<title>Bristol-Myers Squibb And PDL BioPharma Enter Global Alliance To Develop Novel Treatment For Multiple Myeloma</title>
<link>http://www.medicalnewstoday.com/articles/118901.php</link>
<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) today announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzumab, previously known as HuLuc63, currently in Phase I development for multiple myeloma.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118878.php">
<title>Enobia Pharma Initiates Clinical Testing Of Enzyme Replacement Therapy To Treat Hypophosphatasia</title>
<link>http://www.medicalnewstoday.com/articles/118878.php</link>
<description><![CDATA[Enobia Pharma, an emerging biotech   company focused on developing novel therapeutics for serious bone          disorders, announced that the first patient in its clinical program   for hypophosphatasia has been dosed. Enobia is investigating Enzyme               Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and   often crippling genetic bone disorder for which there is no approved   treatment.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118879.php">
<title>BioVex Announces Regulatory Clearance To Commence A Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate For Genital Herpes</title>
<link>http://www.medicalnewstoday.com/articles/118879.php</link>
<description><![CDATA[BioVex Inc, a biotechnology   company developing clinical stage treatments for cancer and the prevention   of infectious disease, announced the UK Medicines and Healthcare   products Regulatory Agency (MHRA) has accepted BioVex's Clinical Trial   Application to conduct a Phase I clinical study testing the safety and            immunogenicity of its lead infectious disease candidate for genital herpes,   ImmunoVEX HSV2.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119384.php">
<title>Society Course Provides Intensive Introduction To Tabletting, UK</title>
<link>http://www.medicalnewstoday.com/articles/119384.php</link>
<description><![CDATA[Graduates and technical staff looking for an intensive introduction to tabletting and the   associated processes are encouraged to register for the course Tabletting Technology for the   Pharmaceutical Industry, organised by the Royal Pharmaceutical Society of Great Britain in   partnership with the Academy of Pharmaceutical Sciences.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119336.php">
<title>New Tool To Help Prevent Medication Mix-Ups Due To Look Alike/Sound Alike Drug Names, Announced By USP</title>
<link>http://www.medicalnewstoday.com/articles/119336.php</link>
<description><![CDATA[The U.S. Pharmacopeial (USP) Convention has announced a new drug safety tool designed to help patients, caregivers, pharmacists, physicians and others in avoiding medication errors that may occur because of drug names that look alike and/or sound alike. This "Drug Error Finder" is a searchable database of almost 1,500 commonly used drugs reported to be involved in medication mix-ups in the U.S. health care system since 2003.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119347.php">
<title>Manhattan Research Announces Top 10 Product Sites Visited By Physicians</title>
<link>http://www.medicalnewstoday.com/articles/119347.php</link>
<description><![CDATA[Diabetes treatment brand sites from Januvia, Actos, Byetta, and Avandia are among the top pharmaceutical product websites in terms of primary care physician visitation, according to a new from pharmaceutical and healthcare market research company Manhattan Research (www.manhattanresearch.com).      Breaking into this year's top product site list are Actos, Actonel, Amitiza, and Aciphex, proving to be successful in increasing physician awareness online.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119348.php">
<title>Trends In Prescription Medication Sharing Among Reproductive-Aged Women</title>
<link>http://www.medicalnewstoday.com/articles/119348.php</link>
<description><![CDATA[Borrowing and sharing of prescription medications is a serious medical and public health concern. A survey of nearly 7,500 women of reproductive age found that this is common practice among more than one-third of this population, according to a report published online ahead of print in Journal of Women's Health, a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper is available free online at ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119326.php">
<title>Pharmacy Technician Certification Board (PTCB) Exhibits At 2008 NACDS Pharmacy &#x26; Technology Conference</title>
<link>http://www.medicalnewstoday.com/articles/119326.php</link>
<description><![CDATA[The Pharmacy Technician Certification Board (PTCB) announced it will be exhibiting at this week's National Association of Chain Drug Store (NACDS) Pharmacy & Technology Conference alongside more than 320 exhibitors and 150 leading retail companies.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119287.php">
<title>FDA Issues New Rules On Product Warning Label Updates For Pharmaceuticals, Medical Devices</title>
<link>http://www.medicalnewstoday.com/articles/119287.php</link>
<description><![CDATA[  FDA last week issued new rules that aim to ensure medication warning labels provide clear and concise information to consumers, the AP/Denver Post reports.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/119180.php">
<title>AARP Launches Four Online Health Tools To Empower Consumers To Make Informed Choices In Care</title>
<link>http://www.medicalnewstoday.com/articles/119180.php</link>
<description><![CDATA[AARP announced that it has added four new health tools to its Web site, to help consumers get trusted, reliable online health information.  These tools will enable people to do everything from choose an excellent doctor or hospital, to better understand and evaluate their own health symptoms, conditions and medicines.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118921.php">
<title>NPA Responds To Research On The Reported Interactions Between Fruit Juices And Medicines</title>
<link>http://www.medicalnewstoday.com/articles/118921.php</link>
<description><![CDATA[The NPA has responded to findings of recent research that implies that consuming apple and orange juice with certain medicines can reduce their effectiveness.    Colette McCreedy, NPA Director of Pharmacy Practice and Chief Pharmacist said: "The effect on grapefruit juice on some medicines is well established and where this applies it is clearly detailed in Patient Information Leaflets. Pharmacists will usually draw this matter to patients' attention when dispensing their medicines.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118868.php">
<title>U.S. District Court Judge Temporarily Blocks Medi-Cal Cuts</title>
<link>http://www.medicalnewstoday.com/articles/118868.php</link>
<description><![CDATA[  A U.S. District Court judge in Los Angeles temporarily blocked implementation of a proposed 10% cut to Medi-Cal payments for doctors, dentists and pharmacies, stating the changes would violate federal laws and reduce the quality of medical care for millions of people, the Sacramento Bee reports (Yamamura/Sanders, Sacramento Bee, 8/20).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118899.php">
<title>Pharmavite LLC Says Vitamin B Study Published In JAMA Is Flawed; Vitamins Meant For Prevention, Not Disease Treatment</title>
<link>http://www.medicalnewstoday.com/articles/118899.php</link>
<description><![CDATA[Pharmavite LLC, maker of Nature Made® vitamins, urged caution against making final judgment on B vitamins for prevention and heart health. The most recent study titled "Mortality and Cardiovascular Events in Patients Treated with Homocysteine-Lowering B Vitamins After Coronary Angiography," is published in the August 20, 2008 edition of the Journal of American Medical Association (JAMA).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118897.php">
<title>California Pharmacists Association Applauds District Court Halt Of Medi-Cal Cuts</title>
<link>http://www.medicalnewstoday.com/articles/118897.php</link>
<description><![CDATA[A Federal District Court in Los Angeles ordered the state of California to stop the ten percent cuts in Medi-Cal reimbursement payments to healthcare providers. The Court found that pharmacies and other Medi-Cal providers and patients were being irreparably harmed as a result of the cuts and that the providers had show a likelihood of success on the merits. Pharmacies were losing money on nearly every Medi-Cal transaction and many pharmacies have been forced to turn away Medi-Cal patients.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118765.php">
<title>U.S. Pharmacopeia Inaugurates New Facility In S&#xC3;&#xA3;o Paulo</title>
<link>http://www.medicalnewstoday.com/articles/118765.php</link>
<description><![CDATA[The U.S. Pharmacopeial  (USP) Convention announces the official opening of its newest international site located in the WTorre Technology Park, SÃ£o Paulo, Brazil. The USP-Brazil facility supports USP's international public health mission to improve the health of people around the world through public standards and related programs that help ensure the quality and safety of medicines and foods.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118709.php">
<title>Trust Announces Practice Research Award Winner</title>
<link>http://www.medicalnewstoday.com/articles/118709.php</link>
<description><![CDATA[Dr Margaret Watson has been announced winner of the Pharmacy Practice Research Trust's   (the Trust) prestigious 2008 Practice Research Award. The award will be presented at the   British Pharmaceutical Conference (BPC) 2008, on Tuesday 9 September, where Dr Watson   will deliver a 30 minute lecture on her award-winning research.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118628.php">
<title>WellNet Launches Online Social Networking Program For Health Care Coordination</title>
<link>http://www.medicalnewstoday.com/articles/118628.php</link>
<description><![CDATA[  WellNet Healthcare this month will launch a test version of Point to Point Healthcare, a social network linking users' physicians, pharmacists and insurance benefit managers, the Washington Post reports.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118625.php">
<title>The Alliance For Patient Medication Safety Submits Landmark Filing To Be A Patient Safety Organization, USA</title>
<link>http://www.medicalnewstoday.com/articles/118625.php</link>
<description><![CDATA[The Alliance for Patient Medication Safety will file a certification to be a Patient Safety Organization (PSO) with the Agency for Healthcare Research and Quality (AHRQ) .  The Alliance for Medication Safety will serve as the premier national patient-centric medication safety evaluation system in the country.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118484.php">
<title>Calpol 6+ Suspension Sugar Free In Bottles - P To GSL - Anomalous, Unnecessary And Unsafe, Says National Pharmacy Association, UK</title>
<link>http://www.medicalnewstoday.com/articles/118484.php</link>
<description><![CDATA[The NPA believes that the reclassification of the bottle presentation of Calpol Six Plus from P to GSL could compromise patient safety, is anomalous in relation to other paracetamol products and is unnecessary as the product can be obtained in alternative packaging that carries less risk.    Changes to the Prescription Only Medicines Order in 1998 were made to reduce the pack sizes of paracetamol available for sale to the public to prevent both accidental and intentional poisoning.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118406.php">
<title>Industry Experts And Global Regulators To Discuss Oligonucleotide-Based Therapeutics Issues</title>
<link>http://www.medicalnewstoday.com/articles/118406.php</link>
<description><![CDATA[The Drug Information Association (DIA), in collaboration with the FDA, Oligonucleotide Therapeutics Society, Health Canada, and the American Association of Pharmaceutical Scientists, will host the 2nd Conference on Oligonucleotide-based Therapeutics (September 22 - 24; Falls Church, VA).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118408.php">
<title>224,000 Californians Sign Petition Urging The Governor And Legislature To Rescind Medi-Cal Cuts</title>
<link>http://www.medicalnewstoday.com/articles/118408.php</link>
<description><![CDATA[The ten percent Medi-Cal provider cuts that went into effect on July 1, 2008 have already created hardships throughout California for pharmacists and the patients they serve. More and more pharmacies have been forced to stop filling Medi-Cal prescriptions because pharmacies lose money on nearly every prescription filled.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118294.php">
<title>Commonwealth Government Settlement With Pan Pharmaceuticals And Its Former Chief Executive, Australia</title>
<link>http://www.medicalnewstoday.com/articles/118294.php</link>
<description><![CDATA[The Commonwealth Government agreed to settle a civil claim which had been lodged in the Federal Court in Sydney by Pan Pharmaceuticals and its former Chief Executive.   The claim which was part heard in the Federal Court during the past month, related to the Therapeutic Goods Administration's decision in 2003 to suspend Pan's manufacturing licence and recall the medicines it manufactured.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118279.php">
<title>Society Encourages Nominations For Pharmas For Pharmacy Awards 2008, UK</title>
<link>http://www.medicalnewstoday.com/articles/118279.php</link>
<description><![CDATA[The Royal Pharmaceutical Society of Great Britain is encouraging individual and team  nominations for the PHARMAS for Pharmacy Awards 2008, which are being held in  Birmingham on 12 October.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118113.php">
<title>Vascular Screening - Naional Pharmacy Association Responds To DH Consultation, UK</title>
<link>http://www.medicalnewstoday.com/articles/118113.php</link>
<description><![CDATA[The NPA has responded to the Department of Health (DH) Consultation on economic modelling of vascular screening. The NPA is asking for the DH to review the contribution which community pharmacy can make as set out in the consultation document which is not in line with the DH recommendations in the Pharmacy White Paper 'Pharmacy in England Building in Strengths - delivering the future April 2008.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118114.php">
<title>National Pharmacy Association Concerned At Wider Release Of Prescribing Data, UK</title>
<link>http://www.medicalnewstoday.com/articles/118114.php</link>
<description><![CDATA[The NPA has responded to the NHS' Wider Release of Prescribing Data Consultation and expressed concern of the release of potential commercially sensitive data which could affect pharmacies neighbouring GP Surgeries.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118116.php">
<title>National Pharmacy Association Takes Members&#x27; Concerns To Prescription Pricing Division, UK</title>
<link>http://www.medicalnewstoday.com/articles/118116.php</link>
<description><![CDATA[NPA staff visited the Prescription Pricing Division HQ in Newcastle to relay the continuing concerns of pharmacists about the PPD's Capacity Improvement Programme (CIP).     Raj Nutan (NPA Head of Business Development) and Stephen Fishwick (NPA Head of External Relations) were hosted by PPD Managing Director Brian Alexander and his senior staff. The NPA was given assurances that the new system for processing prescription payments is now running more smoothly, after a difficult start.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118049.php">
<title>Researchers Examine Safety Of Internet Prescriber Service Providing Erectile Dysfunction Medications</title>
<link>http://www.medicalnewstoday.com/articles/118049.php</link>
<description><![CDATA[ Online Internet shopping today offers many benefits. You can research a product in the privacy of your own home and purchase most anything by clicking a mouse.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/118039.php">
<title>Adverse Reactions To Antibiotics Send Thousands Of Patients To The ER</title>
<link>http://www.medicalnewstoday.com/articles/118039.php</link>
<description><![CDATA[Adverse events from antibiotics cause an estimated 142,000 emergency department visits per year in the United States, according to a study published in the September 15, 2008 issue of Clinical Infectious Diseases.   "This number is an important reminder for physicians and patients that antibiotics can have serious side effects and should only be taken when necessary," said study author Daniel Budnitz, M.D., at the Centers for Disease Control and Prevention (CDC).]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01877.html">
<title>FDA Clears Test to Help Doctors Manage Heart Transplant Patients</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01877.html</link>
<description><![CDATA[The U.S. Food and Drug Administration announced it has cleared for marketing a non-invasive test that uses molecular expression techniques to assist doctors in managing heart transplant patients post-surgery for potential organ rejection.]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01876.html">
<title>FDA Approves First Bone Marrow Stimulator to Treat Immune-Related Low Platelet Counts </title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01876.html</link>
<description><![CDATA[The U.S. Food and Drug Administration today approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01875.html">
<title>FDA Warns Consumers Not to Eat Certain Mussel Products from Bantry Bay Seafood (August 15)</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01875.html</link>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) is warning consumers against eating certain frozen cooked mussel products made by Bantry Bay Seafoods, imported from Ireland, because they may be contaminated with azaspiracid toxins, a group of naturally occurring marine toxins known to cause nausea, vomiting, diarrhea, and stomach cramps. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01874.html">
<title>FDA Approves First Drug for Treatment of Chorea in Huntington&#x27;s Disease</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01874.html</link>
<description><![CDATA[The U.S. Food and Drug Administration has approved Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington's disease. Chorea is the jerky, involuntary movement that occurs in people with this disease. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01873.html">
<title>FDA Warns Consumers About Potential Problems at Two Baltimore Pharmacies</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01873.html</link>
<description><![CDATA[The U.S. Food and Drug Administration is warning consumers who filled prescriptions at The Medicine Shoppe pharmacies located at 8035A Liberty Road and 5900 Reisterstown Road in Baltimore that they may have received drugs that were either expired or suspected counterfeit. The FDA is particularly concerned because a number of the drugs are for serious diseases and could have an adverse effect on treatment.]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01872.html">
<title>FDA Approves 2008-2009 Flu Vaccines
</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01872.html</link>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) today announced that it has approved this year's seasonal influenza vaccines that include new strains of the virus likely to cause flu in the United States during the 2008-2009 season. The six vaccines and their manufacturers are: CSL Limited, Afluria; GlaxoSmithKline Biologicals, Fluarix; ID Biomedical Corporation of Quebec, FluLaval; MedImmune Vaccines Inc., FluMist; Novartis Vaccines and Diagnostics Limited, Fluvirin; and Sanofi Pasteur Inc., Fluzone.]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01871.html">
<title>FDA Announces Improved Policies Regarding Transparency, Public Disclosure for Advisory Committees </title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01871.html</link>
<description><![CDATA[The Food and Drug Administration today announced several improved policies and procedures strengthening its management of FDA advisory committees. The improvements include stricter limits on financial conflicts of interest for committee members, improved voting procedures, and improvements to the processes for disclosing information pertaining both to advisory committee members and to specific matters considered at advisory committee meetings. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01870.html">
<title>FDA Clears Test that Helps Identify Type of Cancer in Tumor Sample </title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01870.html</link>
<description><![CDATA[The U.S. Food and Drug Administration has cleared for marketing a test that can help health care professionals determine what type of cancer cells are present in a malignant tumor. The Pathwork Tissue of Origin test compares the genetic material of a patient's tumor with genetic information on malignant tumor types stored in a database.]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01869.html">
<title>FDA Extends Consumer Warning on Serrano Peppers from Mexico</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01869.html</link>
<description><![CDATA[Laboratory testing by the U.S. Food and Drug Administration has confirmed that both a sample of serrano pepper and a sample of irrigation water collected by agency investigators on a farm in the state of Nuevo Leon, Mexico, contain Salmonella Saintpaul with the same genetic fingerprint as the strain of bacteria that is causing the current outbreak in the United States. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01868.html">
<title>Federal Agents Seize more than $24 Million in Unapproved New Drugs </title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01868.html</link>
<description><![CDATA[Representatives of the U.S. Food and Drug Administration and the U.S. Marshals Service today seized $24.2 million worth of unapproved new drugs from KV Pharmaceutical Company of St. Louis, Mo. Agents acted after United States Attorney Catherine L. Hanaway filed a civil forfeiture suit and obtained a warrant to seize the unapproved new drug products being made by KV Pharmaceutical. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01867.html">
<title>FDA Approves First Generic Divalproex Sodium to Treat Seizures, Migraine Headaches and Bipolar Disorder</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01867.html</link>
<description><![CDATA[The U.S. Food and Drug Administration today approved the first generic version of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches.]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01866.html">
<title>FDA Advises Against Consumption of American Lobster (Maine Lobster) Tomalley </title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01866.html</link>
<description><![CDATA[The U.S. Food and Drug Administration today warned consumers to avoid eating tomalley in American Lobster (Maine Lobster), regardless of where the lobster was harvested, because of potential contamination with dangerous levels of the toxins that cause Paralytic Shellfish Poisoning (PSP). ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01865.html">
<title>U.S. Grown Jalape&#xF1;o and Serrano Peppers Not Connected to Salmonella Saintpaul Outbreak</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01865.html</link>
<description><![CDATA[The U.S. Food and Drug Administration is advising consumers that jalapeño and serrano peppers grown in the United States are not connected with the current Salmonella Saintpaul outbreak. However, the FDA continues to advise consumers to avoid raw jalapeño peppers--and the food that contains them--if they have been grown, harvested or packed in Mexico.
 ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01864.html">
<title>Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01864.html</link>
<description><![CDATA[At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01862.html">
<title>FDA Lifts Warning About Eating Certain Types of Tomatoes</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01862.html</link>
<description><![CDATA[After a lengthy investigation, the FDA has determined that fresh tomatoes now available in the domestic market are not associated with the current outbreak. As a result, the agency is removing its June 7 warning against eating certain types of red raw tomatoes.]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/interioralaska08_08.html">
<title>Interior Alaska Fish Processors, Inc. Recalls Santa&#x27;s Smokehouse Brand Smoked Keta Salmon (August 13)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/interioralaska08_08.html</link>
<description><![CDATA[The recalled product was sold in random weight portions and packaged in clear plastic vacuum sealed bags with the Santa's Smokehouse "teriyaki style smoked keta salmon" label on it. The only batch subject to the recall will be labeled with the batch number '637', found on the Santa's Smokehouse label.]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/publix08_08.html">
<title>Manufacturer for Publix Brand Vanilla Wafers Issues a Recall for Undeclared Soy
 (August 15)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/publix08_08.html</link>
<description><![CDATA[The manufacturer of Publix Vanilla Wafers is recalling a limited number of 12oz boxes of Vanilla Wafers with a code date of 030409A as they may contain undeclared soy. Persons who have an allergy to soy run the risk of a serious or possible life-threatening allergic reaction if they consume the affected product. The UPC number may be found on the side label below the Nutrition Facts panel: Publix Vanilla Wafers, UPC: 41415-00609]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01875.html">
<title>FDA Warns Consumers Not to Eat Certain Mussel Products from Bantry Bay Seafood (August 15)</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01875.html</link>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) is warning consumers against eating certain frozen cooked mussel products made by Bantry Bay Seafoods, imported from Ireland, because they may be contaminated with azaspiracid toxins, a group of naturally occurring marine toxins known to cause nausea, vomiting, diarrhea, and stomach cramps. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/peppersunlimited08_08.html">
<title>Peppers Unlimited, Inc. Recalls La Torre Jalapeno Nacho Slices  (August 14)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/peppersunlimited08_08.html</link>
<description><![CDATA[Peppers Unlimited, Inc. of Fontana California is voluntarily recalling 580 cases of La Torre Jalapeno Nacho Slices because of possible product contamination caused by a chemical reaction between the product and the can potentially resulting in a swollen and/or ruptured container and significant off flavor.
]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/wholefood08_08.html">
<title>Whole Foods Market Issues Recall on 365 Organic Everyday Value Popcorn, Lightly Salted Due to Undeclared Dairy Allergen (August 14)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/wholefood08_08.html</link>
<description><![CDATA[This product was distributed to and sold in Whole Foods Market retail stores in California, Arizona, Nevada, Kentucky, Maryland, Ohio, Pennsylvania, Virginia, Washington D.C, Connecticut, Maine, Massachusetts, Rhode Island, Oregon, New Jersey, New York and Washington. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/marspetcare08_08.html">
<title>Mars Petcare US Issues Voluntary Recall of Limited Bags of PEDIGREE Complete Nutrition Small Crunchy Bites at Albertsons in Southern California and Las Vegas due to Potential Salmonella Contamination  (August 8)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/marspetcare08_08.html</link>
<description><![CDATA[Mars Petcare US today announced a voluntary recall of limited bags of PEDIGREE® Complete Nutrition Small Crunchy Bites sold in Albertsons stores in Southern California and Las Vegas, Nevada. The pet food is being voluntarily recalled because of potential contamination with Salmonella. There have been no complaints or reports of injury resulting from consumption or handling of the recalled product.
 ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/smenterprise08_08.html">
<title>S and M (USA) Enterprise Corp. Issues Alert on Undeclared Sulfites in Grove Grow Notes Brand Dried Bamboo Fungus Veiled Lady (August 12)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/smenterprise08_08.html</link>
<description><![CDATA[The recall was initiated after routine sampling by New York State Department of Agriculture and Markets food inspectors and subsequent analysis by Food Laboratory personnel revealed the presence of sulfites in Grove Grow Notes brand Dried Bamboo Fungus Veiled Lady which were not declared on the label. The consumption of 10 milligrams of sulfites per serving has been reported to elicit severe reaction in some asthmatics. Anaphylactic shock could occur in certain sulfite sensitive individuals upon ingesting 10 milligrams or more of sulfites]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/hoplee08_08.html">
<title>Hop Lee Trading Co., Inc. Issues Alert on Undeclared Sulfites in Flower Brand Dried Sweet Potato (August 12)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/hoplee08_08.html</link>
<description><![CDATA[Hop Lee Trading Co. Inc. is recalling Flower brand Dried Sweet Potato because it contains undeclared sulfites. Consumers who have severe sensitivity to sulfites run the risk of serious or life-threatening allergic reactions if they consume this product. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/homemade08_08.html">
<title>Home Made Brand Foods Recalls Tuna Salad Because of Possible Health Risk  (August 11)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/homemade08_08.html</link>
<description><![CDATA[Home Made Brand Foods is voluntarily recalling approximately 4890 pounds of Ready-to-Eat Tuna Salad with an expiration date of 8/19/08. This product has the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01873.html">
<title>FDA Warns Consumers About Potential Problems at Two Baltimore Pharmacies</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01873.html</link>
<description><![CDATA[The U.S. Food and Drug Administration is warning consumers who filled prescriptions at The Medicine Shoppe pharmacies located at 8035A Liberty Road and 5900 Reisterstown Road in Baltimore that they may have received drugs that were either expired or suspected counterfeit. The FDA is particularly concerned because a number of the drugs are for serious diseases and could have an adverse effect on treatment.]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/cfsauer08_08.html">
<title>C.F. Sauer Foods Issues Allergy Alert on Undeclared Milk in one lot of Gold Medal Spaghetti Sauce Mix  (August 4)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/cfsauer08_08.html</link>
<description><![CDATA[CF Sauer Foods Inc, of Richmond, VA is recalling all packages of Gold Medal Spaghetti Sauce Mix with the code date as follows: 8119R. People who have an allergy or severe sensitivity to milkrun the risk of serious or life threatening allergic reaction if they consume these products. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/wegmans07_08.html">
<title>Manufacturer for Wegmans Brand Sorbet Issues an Allergen Alert for Undeclared Milk on a Limited Number of Wegmans Brand Sorbets  (July 31)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/wegmans07_08.html</link>
<description><![CDATA[The manufacturer of Wegmans Sorbet is recalling a limited number of 16 oz. Wegmans brand Sorbets because they may contain undeclared milk. People who have an allergy to milk run the risk of a serious or possible life-threatening allergic reaction if they consume the affected products.]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01869.html">
<title>FDA Extends Consumer Warning on Serrano Peppers from Mexico</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01869.html</link>
<description><![CDATA[Laboratory testing by the U.S. Food and Drug Administration has confirmed that both a sample of serrano pepper and a sample of irrigation water collected by agency investigators on a farm in the state of Nuevo Leon, Mexico, contain Salmonella Saintpaul with the same genetic fingerprint as the strain of bacteria that is causing the current outbreak in the United States. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/eglabs07_08.html">
<title>EG Labs Announces Urgent Nationwide Voluntary Recall of ALL LOTS of Viapro 375 mg Capsules, due to a Potentially Harmful Ingredient </title>
<link>http://www.fda.gov/oc/po/firmrecalls/eglabs07_08.html</link>
<description><![CDATA[EG Labs, LLC, announced today that it is conducting a nationwide voluntary recall of all lots of its supplement product sold under the brand name, Viapro, in 375mg capsules. EG Labs, LLC. is conducting this recall after being informed by representatives of the Food and Drug Administration (FDA) that lab analysis by FDA of a sample from one lot of the product revealed that it contained a potentially harmful undeclared ingredient, thio-methisosildenafil. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/vitafood07_08.html">
<title>Vita Food Products Issues Alert Regarding Vita Nova Salmon (July 25)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/vitafood07_08.html</link>
<description><![CDATA[The product that is the subject of this public announcement and recall are packages (deep dark blue in color) of smoked salmon that bear the Vita logo in the upper left corner on the part of the packaging that is immediately visible to the consumer. Each package contains 4-10 bacon-style slices (total 3 oz.) of smoked salmon; the slices are contained in a vacuum pack within a box that is 4" wide by 7.5" in length by 1/2" in thickness. IMPORTANT: The Code Date of 11/16/08 198 is on the left end flap of each package. This announcement and recall only applies to packages that bear that CODE DATE.]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/jackdistribution07_08.html">
<title>Jack Distribution, LLC. Issues a Voluntary Nationwide Recall of all Lots of Rize 2 The Occasion Capsules and Rose 4 Her Capsules, Products Marketed as Dietary Supplements, Containing an Undeclared Ingredient(July 28) </title>
<link>http://www.fda.gov/oc/po/firmrecalls/jackdistribution07_08.html</link>
<description><![CDATA[Jack Distribution, LLC, and its wholesale distributors G and N works, Inc., and Devine Distribution, Inc., announced today that they are conducting a voluntary nationwide recall of all lot numbers of the company's supplement products sold under the brand names Rize 2 The Occasion and Rose 4 Her. New lots of Rize 2 and Rose 4 her (not subject to this recall) will contain lot numbers beginning in "BL".]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/publix07_08.html">
<title>Publix Issues Recall for No Sugar Added Cherry Pie (July 24)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/publix07_08.html</link>
<description><![CDATA[Publix Super Markets is issuing a voluntary recall on three codes of No Sugar Added Cherry Pie with a sell-by-date of July 8 – July 27. UPC numbers for the affected product may be found on the back label below the Nutritional Facts panel: Publix NSA 8inch Cherry Pie, UPC: 41415-65990; Publix NSA 1/2 Cherry Pie, UPC: 03000-00225; and Publix NSA 1/4 Cherry Pie, UPC: 41415-66990. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/sausea07_08.html">
<title>Sau-Sea Foods, Inc. Issues Allergy Alert on Undeclared Egg in Smoked Salmon Spread in 7.5 Ounce Plastic Tub With Snap Lid (July 18)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/sausea07_08.html</link>
<description><![CDATA[Sau-Sea foods, Inc, of Water Mill NY is recalling all tubs of SMOKED SALMON Spread with the sell by dates as follows: 072308, 082708, 092408, 1 12508, 03 1309. People who have an allergy or severe sensitivity to egg run the risk of serious or life threatening allergic reaction if they consume these products.]]></description>
</item>

<item rdf:about="http://www.fda.gov/bbs/topics/NEWS/2008/NEW01864.html">
<title>Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product (July 24)</title>
<link>http://www.fda.gov/bbs/topics/NEWS/2008/NEW01864.html</link>
<description><![CDATA[At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient. ]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/agricola_zaragoza07_08.html">
<title>Agricola Zaragoza, Inc. Recalls Jalapeno Peppers Because of Possible Health Risk (July 21)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/agricola_zaragoza07_08.html</link>
<description><![CDATA[The recall is a result of sampling by FDA, which revealed that these Jalapeno Peppers were contaminated with the same strain of Salmonella Saintpaul responsible for the current Salmonella outbreak. It is unknown at this time which, if any, of the more than 1,200 illnesses reported to date are related to this particular product or to the grower who supplied this product.  Distribution of these products has been suspended while FDA, the Texas Department of State Health Services and the company continue their investigation as to the source of the problem.
]]></description>
</item>

<item rdf:about="http://www.fda.gov/oc/po/firmrecalls/domega07_08.html">
<title>Domega International Co., Ltd. Issues an Alert on Undeclared Sulfites in Korica Brand Mut Gung Sweetened Ginger (July 16)</title>
<link>http://www.fda.gov/oc/po/firmrecalls/domega07_08.html</link>
<description><![CDATA[The recalled Korica Brand Mut Gung Sweetened Ginger is sold in uncoded 7 oz plastic tubs and is a product of Vietnam. The product was sold nationwide.]]></description>
</item>

</rdf:RDF>